Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus

Kong, Kok Ooi; Tan, Alvin Wai Kit; Thong, Bernard Yu‐Hor; Lian, Tsui Yee; Cheng, Yuan; Teh, Cheng Lay; Koh, Ee Tzun; Chng, H H; Law, Weng Giap; Lau, Tang Ching; Leong, Khai Pang; Leung, Bernard P.; Howe, Hwee Siew

doi:10.1111/j.1365-2249.2009.03880.x

Cited by 68 publications

(66 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have showed that CCL-2 and CXCL 10 were higher in SLE patients and plasma IL-18 concentration showed strong positive correlation with inflammatory chemokines; CXCL 10 and may be better indicators to assess the current disease activity, prediction of future disease flares and overall clinical decision-making. Our report shows elevated CXCL 10 levels in sera from SLE patients who could serve as good indicators of severity and activity of disease, as suggested by studies conducted at cellular level (Kong et al, 2009). Also, a good association between CXCL 10 and ESR in SLE may suggest Th1 chemokine activity in the disease which may have important roles in leukocyte homing, in the perpetuation of inflammation and concomitant tissue damage (Lee et al, 2009).…”

Section: Discussionsupporting

confidence: 58%

“…The chemokine CCL 2 (Monocyte chemoattractant protein-1/MCP-1) is known as a Th1 chemokine and has an important role in homing of lymphoid cells to the zone of inflammation (Shimizu et al, 2005). Another chemokine CXCL 10 (Interferon-inducible protein-10/IP-10) upon binding to its ligand CXCR 3 attracts Th1 cells and promotes its maturation (Kong et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interplay of Cytokines and Chemokines in the Pathogenesis of Systemic Lupus Erythematosus

Shah

Wanchu

Bhatnagar

2011

American Journal of Immunology

View full text Add to dashboard Cite

Problem statement: Dysbalance of T-helper-cell (Th) cytokines and chemokines was suggested to contribute to the pathogenesis of Systemic Lupus Erythematosus (SLE). Recent reports suggest the involvement of cytokines and chemokines in the pathogenesis of SLE, but their relationship with each other and particularly in the severity of disease, was not yet understood. We analyzed the interaction between cytokines and chemokines and their relationship with severity of disease in SLE. Approach: Serum levels of cytokines and chemokines were determined by ELISA and severity of disease were measured by by using SLE Disease Activity Index (SLEDAI) score. Results: The serum levels of cytokine (IL-2, IFN-γ, IL-6, IL-10 and IL-12) and chemokine (CCL2, CCL5 and CXCL10) were variably associated with disease activity in SLE patients. Strict interaction between cytokines and chemokines was observed in SLE patients. Interleukin-6 was positively correlated with CCL5 while IL-12 was also analogous correlated with CXCL10 in SLE patients. The kidney involvement in SLE patients was related with intense increased levels of cytokines (IFN-γ, IL-12) and chemokines (CCL2, CCL5 and CXCL10). Conclusion: These data suggest that interplay of cytokines and chemokines may be involved in the severity of disease. Also, a better understanding of the cytokines and chemokines interaction may likely to provide important clues to the pathogenic mechanism and pave the way toward more effective therapeutics.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Introductionmentioning

confidence: 99%

Interplay of Cytokines and Chemokines in the Pathogenesis of Systemic Lupus Erythematosus

Shah

Wanchu

Bhatnagar

2011

American Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…18 20 Furthermore, elevated levels of IP-10 were found in patients with pSS related to T-cell infiltration into salivary glands 2122 However, IP-10 has not yet been studied as a biomarker of systemic disease activity in pSS.…”

Section: Introductionmentioning

confidence: 99%

SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome

et al. 2016

View full text Add to dashboard Cite

ObjectivesTo evaluate the interferon (IFN) biomarkers sialic acid binding Ig like lectin 1 (SIGLEC1, CD169) and IFN-γ-inducible protein-10 (IP-10) in patients with primary Sjögren's syndrome (pSS).Methods31 patients fulfilling the American-European criteria for pSS were included. Disease activity was obtained by EULAR Sjögren's syndrome disease activity index (ESSDAI). SIGLEC1 expression on monocytes was analysed using flow cytometry. IP-10 concentrations were determined using Bioplex human Cytokine 27-plex kit. Spearman rank test (SRT) was used for correlation analysis and Mann-Whitney U (MWU) to test for differences between glandular and extraglandular manifestations.ResultsAn activated IFN system was detected by an upregulation of SIGLEC1 expression in 64.5% and by elevated serum level of IP-10 in 78.9% of our patients with pSS. In a subsequent analysis SIGLEC1 expression was found to be upregulated more frequently in patients with extraglandular manifestations (16/16, 100%) compared to patients with exclusively glandular involvement (4/15, 27%). SIGLEC1 expression could significantly discriminate between these two disease subgroups (p=0.0001, MWU) with a positive predictive value (PPV) of 80% for extraglandular disease. Moreover, the expression correlated with disease activity (p=0.005, r=0.54, SRT). Serum IP-10 levels neither differed significantly between glandular and extraglandular disease nor correlated with ESSDAI.ConclusionsOur results indicate that increased SIGLEC1 expression characterises patients with systemic involvement and high disease activity. Therefore, SIGLEC1 determination might be of value for subset definition, risk stratification and differential therapeutic considerations in pSS.

show abstract

“…31,63 SIGLEC1 and CD64 expression on monocytes also correlated longitudinally with SLE activity. 64 IFN biomarkers have prognostic utility.…”

Section: Type I Interferonmentioning

confidence: 81%

Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE

Biesen

Rose

Hoyer

et al. 2016

Lupus

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) can be a mysterious disease, presenting with extremely divergent clinical phenotypes. Already, biomarkers are very helpful tools for diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course and stratified therapy, and they hold the key to personalized medicine in SLE. We summarize the clinical information that can only be supplied by autoantibodies, complement components and interferon biomarkers in this diverse disease.

show abstract

Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus

Cited by 68 publications

References 32 publications

Interplay of Cytokines and Chemokines in the Pathogenesis of Systemic Lupus Erythematosus

Interplay of Cytokines and Chemokines in the Pathogenesis of Systemic Lupus Erythematosus

SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome

Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE

Contact Info

Product

Resources

About